Experimental drug miglustat tested for rare batten disease

NCT ID NCT05174039

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested the drug miglustat in 6 adults aged 17 and older with CLN3 Batten disease, a rare genetic disorder that causes nerve damage. The goal was to see if the drug is safe and to find the best dose over 2 years. Researchers tracked side effects and how the drug moved through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

miglustat

What this could lead to

If it works, this could point toward a treatment that slows or manages CLN3 Batten disease in older patients.

What could go wrong

This was a very small, early-phase trial with only 6 people, so results may not apply widely. The drug may cause side effects and may not improve the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BATTEN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuronal ceroid lipofuscinosis 3 Neuronal Ceroid-Lipofuscinoses

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Texas Children Hospital

    Houston, Texas, 77030, United States